Obama Care is now Obama Scare-
its going green in the next 10 minutes. That slow crawl down was so obviously orchestrated by the MM to pick up some cheap shares in advance of the big meeting next week.
The Company estimates that the cycling of the impact of pre-storm sales on prior year’s results had a negative impact of 1.4% on front-end same store sales results and 0.3 percent on comparable store prescription count growth, as prior year results benefited from an increase in sales in the days immediately preceding Superstorm Sandy. The Company anticipates that the cycling of the impact of Superstorm Sandy will have a positive impact on November’s sales results.
"It was clear from the beginning that there were going to be some winners and losers," said Timothy Jost, a law professor at Washington and Lee University in Virginia, who supports the health overhaul. "But the losers are calling reporters, and the winners can't get on the website."
Said Many companies earnings are a mirage. Market setting up for a big drop. Carl probably just shorted the market. Must be nice to able to legally manipulate the market by opening your mouth.
This could be the one stock I have dreamed about for years. How many times have we seen a stock go from $5 to $100? I haves seen quite a few and almost all were tech stocks.
another article out today
Oppenheimer had a meeting with Himax Technologies, Inc (NASDAQ:HIMX)’s management. They have declared that the management has become more bullish over the past fortnight. The management has reported that the Google-Glass win has led to a notable interest in its own LCOS micro-display solutions and that many other companies have shown an interest in it.
A couple of weeks ago, Oppenheimer had upped its price target for Himax Technologies, Inc (NASDAQ:HIMX) from $9.00 to $12.00. They had also lauded the company’s better than expected outlook for its LCOS business. The note that had been issued by Oppenheimer came on the heels of the one that had been issued by Craig-Hallum.
In Wednesday’s trading, Himax Technologies, Inc (NASDAQ:HIMX) stock rose by 6.75%. The opening price of the stock was $9.41 which touched an intraday high of $9.77 and closed at $9.73. Approximately 21.56 million shares were bought and sold and the average volume of shares traded over a 30 day period was 10.77 million. The company has a market cap of $1.65 billion.
About the company
Himax Technologies, Inc (NASDAQ:HIMX) came into existence on 26 April 2005. It is involved in designing, developing and marketing semiconductors that are key components of flat-panel displays. Its primary products are display-drivers for large-sized, thin-film transistor liquid-crystal display panels. These are mainly used in desktop-monitors, notebook-computers and TV’s. The company also manufactures display-drivers for small as well as medium-sized TFT-LCD panels.
These are mainly used in mobiles and other consumer electronics products like tablet PC’s, digital cameras, mobile-gaming devices, portable-digital versatile disc players, digital-photo frame as well as in car navigation displays. Himax Technologies, Inc (NASDAQ:HIMX) also offers display-drivers that use LTPS technology and OLED technology and. It works very closely with optical engine manufacturers, camera module manufacturers, and television-system manufacturers for different non-driver products.
Both Walgreen and CVS appear to be relatively low-risk plays on the future of health care in our country. But what about the high-flying Rite Aid?
Just a couple of years ago, Rite Aid was in the proverbial dumpster. During its recovery, sales have yet to make a tremendous comeback, but the company has improved margins substantially. Last year, the company had a negative profit margin that turned back to black in the past four quarters. In its recent guidance, management predicted a 1% margin for the full year.
In such a low-margin business, any sustainable improvement in efficiency goes a long way. Walgreen and CVS have margins above 3%. If Rite Aid continues its margin expansion quest, the bottom line has the potential to grow far, far faster than its peers. Even at a premium valuation to its peers, the company's stock is not overpriced.
All three of the drugstore giants hold their merits as investments in the coming years, and valuation does not keep any from being a good deal today. But the most bang for your buck may come from the fast riser, Rite Aid, which could still go higher yet.
I hope we don't get bought out soon because it would be for less that $20 (100% premium). Let someone buy us at $100 in 3 years when google glass is as ubiquitous as the smart phone. I predict that the Chinese will be the early adopters followed by India and then the U.S. China and India represent 30% of the global population or about 3 billion people. If 1% of the population buys google glass, that's 30 million. 5% = 150 million, 10% = 300 million. If those numbers sound high, check this out- there are more computers and mobile devices now than the entire world population =7 BILLION +
Himax Technologies (HIMX) will be a key supplier for the growing AR space. It has appreciated just slightly north of the $10 threshold. The company is coming off a game-changing agreement with Google Inc. (GOOG). On July 22 the company announced that Google agreed to make a minority investment in a subsidiary, Himax Display (HDI). Himax Display fabricates the Liquid Crystal on Silicon (LCOS) chips and modules necessary for the deployment of Google Glass' head-mounted display.
Operationally, Google's investment will allow the company to make the necessary production improvements to handle the expected raft of orders that will attend the commercialization of the Google Glass. Currently, the company does not have infrastructure to hand the anticipated volume.
You don't want to be an uncritical lemming, but HDI has a peerless investor pedigree. Google is joining Silicon Valley stalwarts Khosla Ventures and Intel Capital Corp. These venture funds have tremendous track records. They perform rigorous due diligence, and as such their investment is a validation of both the profitability of the technology and the competence of the management team. A chance to partially outsource some of your due diligence to these firms is not an opportunity to sneer at.
An investment in the public equity of the parent will get you great exposure to HDI with the additional benefit of diversification. HIMX's technology has a very broad user base (phone, tablet, automotive applications, CMOS sensors, wafer level optics, etc.) and isn't nearly as dependent on the success of one large client. Himax's earnings last quarter were solidly in line with optimistic guidance. And the company looks poised to compound on its past success.
Shares of Rite Aid Corp. (RAD) achieved a new 52-week high of $5.35 on Oct 17, 2013, beating its previous high of $5.33 on Oct 7. Moreover, the drugstore chain retailer eventually closed trade at its new 52-week peak, reflecting a solid year-to-date return of approximately threefold. The average volume of shares traded over the last 3 months was approximately 26,872K.
Moreover, the company currently trades at a forward P/E of 24.8x, a 53% premium to the peer group average of 16.21x. The company’s premium valuation is justified, given its long-term earnings per share (EPS) growth rate of 17.5% versus the peer group’s growth rate of 13.7%.
We believe that the strong price appreciation is primarily attributable to the company’s comparable-store sales (comps) growth for September. This was the fourth consecutive month when Rite Aid posted positive comps results.
Apart from this, consistent positive earnings in the past four quarters were a tailwind. Rite Aid, which witnessed declining sales and weak bottom-line results in the recent past, is now showing signs of improvement, thanks to the company’s cost reduction initiatives and improvement in store-level performance.
This Zacks Rank #1 (Strong Buy) stock has outperformed the Zacks Consensus Estimate five times in the trailing six quarters. In the recently concluded quarter, Rite Aid posted adjusted earnings of 8 cents per share, which fared better than the Zacks Consensus Estimate of a loss of 4 cents and the year-ago comparable quarter’s loss of 5 cents.
Furthermore, on the back of better-than-expected first-half financial results and a stronger second-half performance than what was projected earlier, management raised its fiscal 2014 guidance. Rite Aid now expects earnings in the range of 18–27 cents per share for the fiscal, up from the previous range of 1–16 cents. Currently, the Zacks Consensus Estimate stands at 22 cents per share.
Rite Aid utilized additional resources such as the Wellness+ customer loyalty program and the Flu Immunization program to boost customers’ demand amid the challenging macroeconomic environment. The company’s customer loyalty program has been successful in attracting customers. This is evident from the fact that Wellness+ members in fiscal 2013 contributed 79% of front-end sales, compared with 68% in fiscal 2012.
On the cost front, the company is focusing on generating cost savings through centralized indirect procurement of drugs and reduction in supply chain costs. We believe that these programs and initiatives will facilitate the company to increase its customer base and generate long-term profitability.
Apart from Rite Aid, other retail stocks such a